Race Oncology Ltd has released a press release.
Quarterly Activity Report & Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- RC220 cGMP Manufacturing Complete
- Bisantrene shows potent anticancer activity in AML models
- S&P DJI Announces March 2024 Quarterly Rebalance
- Race Receives $4.0m R&D Tax Refund for Financial Year 2023
- December 2023 Preclinical & Clinical Program Update
Later from Racura Oncology
- Bisantrene with Decitabine Enhances Cancer Cell Killing
- US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
- Bisantrene Highly Active in a Multiple Myeloma Mouse Model
- FDA RPD Designation Granted for RC220 Bisantrene
- Race Appoints George Clinical for Phase 1 Trial of RC220
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology